Abstract
Treatment of metastatic melanoma is a challenge for clinicians as most agents have failed to demonstrate improved survival in phase III trials. Despite the immunogenicity of this tumor entity, different immunological interventions including cytokine therapy, vaccination, biochemotherapy or allogeneic hematopoietic cell transplantation did not lead to a satisfactory response. However, continuous investigation on the immune mediated rejection of melanoma cells has led to the development of effective antibodies blocking cytotoxic T-lymphocyte antigen-4 (CTLA-4), a critical negative regulator of the antitumor T-cell response. Based on data from rodent models, the anti-CTLA-4 antibody ipilimumab was developed into clinical studies where it had encouraging activity in advanced melanoma with unusual response patterns. As in most immunostimulatory therapies, acute toxicities were severe and clearly mechanism-related. Although some patients developed signs of autoimmunity, the toxicities were overall manageable and mostly reversible.
This review summarizes different immunotherapeutical approaches against melanoma that have been applied in the past and focuses on CTLA-4 blockade with respect to its mechanism, clinical effectiveness and immunological side effects.
Keywords: Allogeneic transplantation, CTLA-4, immunotherapy, malignant melanoma
Current Stem Cell Research & Therapy
Title:Immunotherapy for Malignant Melanoma Robert
Volume: 7 Issue: 3
Author(s): Robert Zeiser, Marc Schnitzler, Hana Andrlová, Tina Hellige and Frank Meiss
Affiliation:
Keywords: Allogeneic transplantation, CTLA-4, immunotherapy, malignant melanoma
Abstract: Treatment of metastatic melanoma is a challenge for clinicians as most agents have failed to demonstrate improved survival in phase III trials. Despite the immunogenicity of this tumor entity, different immunological interventions including cytokine therapy, vaccination, biochemotherapy or allogeneic hematopoietic cell transplantation did not lead to a satisfactory response. However, continuous investigation on the immune mediated rejection of melanoma cells has led to the development of effective antibodies blocking cytotoxic T-lymphocyte antigen-4 (CTLA-4), a critical negative regulator of the antitumor T-cell response. Based on data from rodent models, the anti-CTLA-4 antibody ipilimumab was developed into clinical studies where it had encouraging activity in advanced melanoma with unusual response patterns. As in most immunostimulatory therapies, acute toxicities were severe and clearly mechanism-related. Although some patients developed signs of autoimmunity, the toxicities were overall manageable and mostly reversible.
This review summarizes different immunotherapeutical approaches against melanoma that have been applied in the past and focuses on CTLA-4 blockade with respect to its mechanism, clinical effectiveness and immunological side effects.
Export Options
About this article
Cite this article as:
Zeiser Robert, Schnitzler Marc, Andrlová Hana, Hellige Tina and Meiss Frank, Immunotherapy for Malignant Melanoma Robert, Current Stem Cell Research & Therapy 2012; 7 (3) . https://dx.doi.org/10.2174/157488812799859883
DOI https://dx.doi.org/10.2174/157488812799859883 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
α7 Nicotinic Acetylcholine Receptor Subunit in Angiogenesis and Epithelial to Mesenchymal Transition
Current Drug Targets Ghrelin and the Brain-gut Axis as a Pharmacological Target for Appetite Control
Current Pharmaceutical Design Genetic Predisposition to Parkinson’s Disease and Cancer
Current Cancer Drug Targets The Role of Thrombomodulin in Atherosclerosis: From Bench to Bedside
Cardiovascular & Hematological Agents in Medicinal Chemistry The Influence of Lipophilicity on the Classification of Antitumor Acridinones Evaluated by Principal Component Analysis
Current Pharmaceutical Analysis Editorial (Thematic Issue: Current Treatments for Skin Cancer Part 2)
Current Cancer Therapy Reviews Targeting MDM4 as a Novel Therapeutic Approach for Hematologic Malignancies
Current Cancer Drug Targets APO2L/TRAIL: New Insights in the Treatment of Autoimmune Disorders
Recent Patents on Inflammation & Allergy Drug Discovery Plant Polyphenols: Natural and Potent UV-Protective Agents for the Prevention and Treatment of Skin Disorders
Mini-Reviews in Medicinal Chemistry Targeting the Endocannabinoid System for the Treatment of Cancer – A Practical View
Current Topics in Medicinal Chemistry Interleukin-24: A Molecule with Potential Anti-Cancer Activity and a Cytokine in Search of a Function
Endocrine, Metabolic & Immune Disorders - Drug Targets The Role of Intracrine Androgen Metabolism, Androgen Receptor and Apoptosis in the Survival and Recurrence of Prostate Cancer During Androgen Deprivation Therapy
Current Drug Targets Prioritizing Disease Genes by Using Search Engine Algorithm
Current Bioinformatics Natural Compounds as Anticancer Agents Targeting DNA Topoisomerases
Current Genomics Withdrawal Notice: Recent Developments in Anti-Cancer Activity of Compounds Containing the Thioether Group
Anti-Cancer Agents in Medicinal Chemistry Osteoprotegerin and Diabetes-Associated Pathologies
Current Molecular Medicine Polycation-Based Ternary Gene Delivery System
Current Drug Metabolism Tissue-Based Approaches to Study Pharmacodynamic Endpoints in Early Phase Oncology Clinical Trials
Current Drug Targets Expression of Rab3b in Human Glioma: Influence on Cell Proliferation and Apoptosis
Current Pharmaceutical Design Law-Medicine Interfacing: Patenting of Human Genes and Mutations
Recent Patents on DNA & Gene Sequences